公开(公告)号：EP4137481A1

公开(公告)日：2023-02-22

申请号：EP21789367.6

申请日：2021-04-15

申请人： Teijin Pharma Limited

发明人： SUGIYAMA, Sakae ,  YOKOSAKA, Takuya ,  MINAMIZONO, Kunio ,  KAWANA, Asahi ,  KANEKO, Toshiyuki ,  MARUYAMA, Akinobu ,  SASAKI, Kosuke ,  HOSODA, Shinnosuke ,  KOSHIMIZU, Masaki ,  TAKEUCHI, Susumu ,  KATO, Kenta ,  CHAKKA, Nagasree ,  JOHNSON, Brett M. ,  WHITE, Ryan d. ,  ZHAO, Wei

IPC分类号： C07D213/74 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61P3/10 ,  A61P7/10 ,  A61P9/04 ,  A61P9/12 ,  A61P11/00 ,  A61P13/12 ,  A61P21/04 ,  A61P31/04 ,  A61P35/00 ,  A61P43/00 ,  C07D237/20 ,  C07D239/34 ,  C07D239/42

摘要： A compound indicated by formula (I) or a pharmacologically acceptable salt thereof is provided as a compound that can be a therapeutic or prophylactic drug for TRPC6-related diseases, such as nephrotic syndrome, membranous nephropathy, acute renal failure, septicemia, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumor, and muscular dystrophy. (In the formula, Ar 1 , Ar 2 , X 1 -X 3 , R 1 , R 3 , R 7 , R 8 , L 1 , and L 2 are as defined in the specifications.)